Sorafenib and azacitidine as salvage therapy for relapse of FLT3‐ITD mutated AML after allo‐SCT

• DOI: 10.1111/ejh.12832
• Publication Date: 2016-11-28T16:03:17Z
• Authors: Christina Rautenberg; Kathrin Nachtkamp; Ariane Dienst; Pia Verena Schmidt; Claudia Heyn; Mustafa Kondakci; Ulrich Germing; Rainer Haas; Guido Kobbe; Thomas Schroeder
• Keywords: Azacitidine

Abstract Objective Patients with acute myeloid leukemia ( AML ) carrying FLT 3‐ ITD mutations +) who relapse after allogeneic transplantation (allo‐ SCT have a very dismal prognosis the currently available treatment options. Methods We treated eight patients + had relapsed in median 91 d (range, 28–249) following allo‐ combination of multikinase inhibitor sorafenib and DNA methyltransferase azacitidine (Aza). Results received five cycles Aza 2–9) daily dosage 750 mg (range 400–800) for 129 61–221). Six donor lymphocyte infusions DLI number two per patient 1–4). Following this treatment, four (50%) achieved complete remission three them molecular remission. Median duration CR was 182 158–406), remain ongoing 406 168 d. overall survival 322 108–574 d) being alive. Conclusion Taken together, sorafenib, Aza, shows promising efficacy deserves further evaluation larger groups.